A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients with Advanced or Recurrent Solid Tumors November 7, 2023
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients with Advanced Solid Tumors November 7, 2023